QL1706

QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer

A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Chemoimmunotherapy

SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer

SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer

A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors

A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC

QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors

Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC